Obviousness

Obviousness Analysis of US Patent 11041020 under 35 U.S.C. § 103

This analysis aims to determine if the claims of US patent 11041020, which focuses on methods and compositions for treating active Psoriatic Arthritis (PsA) using a specific anti-TNF antibody (golimumab, identified by SEQ ID NOs: 36 and 37 for heavy and light chains, respectively), would have been obvious to a person having ordinary skill in the art (POSA) at the time of the invention (priority date January 30, 2017).

Background Prior Art

Prior to the priority date of January 30, 2017, the general concept of anti-TNF therapy for autoimmune diseases, including PsA, was well-established. Golimumab (Simponi) as a human anti-TNFα monoclonal antibody was approved by the US FDA in April 2009 for the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS) via subcutaneous (SC) injection. This demonstrates that the antibody itself and its efficacy in PsA were known.

Furthermore, prior to the patent's priority date, intravenous (IV) golimumab (Simponi Aria) had been FDA approved in 2013 for the treatment of moderately to severely active rheumatoid arthritis in combination with methotrexate. The recommended dosage for RA was 2 mg/kg administered via IV infusion over 30 minutes at Weeks 0 and 4, and every 8 weeks thereafter.

Crucially, the patent itself acknowledges that "FIG. 18 shows diagram of the study design for trial of Simponi (golimumab), administered intravenously, in subjects with active Psoriatic Arthritis (PsA)". This indicates that a clinical trial investigating IV golimumab for active PsA was either ongoing or its design was known at the time of the invention. Indeed, publicly available information confirms that the Phase 3 GO-VIBRANT study, which evaluated IV golimumab for active PsA using a 2 mg/kg dose at weeks 0 and 4, and then every 8 weeks, was underway and its data was presented at the 2017 Annual European Congress of Rheumatology in Madrid (before the FDA approval for IV PsA). The FDA was actively reviewing Simponi Aria for PsA and AS based on these Phase 3 studies prior to October 2017. The FDA approval for IV Simponi Aria for PsA ultimately occurred on October 20, 2017.

Obviousness Arguments

The independent claims of US 11041020 generally cover methods and compositions for treating active Psoriatic Arthritis using an anti-TNF antibody with HC SEQ ID NO:36 and LC SEQ ID NO:37 (golimumab) via IV infusion, often specifying a 2 mg/kg dose at Weeks 0, 4, and then every 8 weeks, to achieve particular clinical responses (e.g., ACR20 at week 14).

Combination of Prior Art: Golimumab (SC) for PsA + IV Golimumab for RA + Known Efficacy of Anti-TNF in PsA + Ongoing Clinical Trials of IV Golimumab for PsA

A POSA, as of January 30, 2017, would have been aware of the following:

1. Golimumab's established efficacy in Psoriatic Arthritis (PsA) via subcutaneous (SC) administration: Golimumab (Simponi) was approved for PsA in 2009 for SC injection. This provided a clear expectation that golimumab, regardless of the route of administration, would be an effective treatment for PsA.
2. Golimumab's established intravenous (IV) administration for Rheumatoid Arthritis (RA): IV golimumab (Simponi Aria) was approved for RA in 2013, with a well-defined dosage regimen of 2 mg/kg via IV infusion over 30 minutes at Weeks 0 and 4, and every 8 weeks thereafter. RA and PsA are both chronic inflammatory rheumatic diseases, often treated with similar classes of biologics, including TNF inhibitors.
3. The known role of TNF-α in PsA pathophysiology: Elevated levels of TNF-α are known to play a role in the pathophysiology of psoriatic arthritis, making anti-TNF therapy a rational approach.
4. The existence and design of the GO-VIBRANT trial: Prior to the priority date, the GO-VIBRANT Phase 3 study was evaluating IV golimumab for active PsA, specifically using the 2 mg/kg IV infusion regimen at weeks 0 and 4, and then every 8 weeks. The primary endpoint of this trial was ACR20 response at week 14. Data from this study, showing improvement in joint and skin symptoms, was presented in 2017.

Motivation to Combine:

A POSA would have been motivated to combine these pieces of prior art for several reasons:

• Established Mechanism of Action: Given that golimumab (SC) was already approved and effective for PsA, and IV golimumab was effective for RA (a related inflammatory condition), it would have been a logical and obvious step to investigate the IV formulation of golimumab for PsA. The mechanism of action (TNF-α inhibition) is the same regardless of the delivery method.
• Known Dosage and Regimen: The 2 mg/kg IV infusion regimen (Weeks 0, 4, then every 8 weeks) was already established and approved for IV golimumab in RA. It is common practice in pharmaceutical development to explore similar dosage regimens for related indications, especially when the drug itself (golimumab) is already known to be effective in the disease (PsA).
• Clinical Need and Preference: There is a continuous need for new treatment options and alternative administration routes for patients with chronic diseases like PsA. Some patients may prefer IV administration over SC injections, and a 30-minute infusion time would be considered an important new treatment option. Therefore, exploring an IV formulation for PsA would address a known patient and clinical need.
• Predictable Outcomes: The American College of Rheumatology (ACR) criteria (ACR20, ACR50, ACR70) and Psoriasis Area and Severity Index (PASI) scores are standard clinical endpoints for evaluating the efficacy of treatments for PsA and other rheumatic diseases. Given golimumab's known efficacy in PsA (via SC) and RA (via IV), achieving a clinical response as measured by these standard metrics (e.g., ACR20 at week 14) would be an expected outcome, not a surprising one, when applying the IV formulation and established RA dosing regimen to PsA patients. The patent itself provides clinical efficacy data at week 14 and week 24, including ACR20 results, for IV golimumab in PsA, which were generated from the GO-VIBRANT study that was already underway.

Therefore, the claims specifying the use of golimumab (HC SEQ ID NO:36, LC SEQ ID NO:37) via IV infusion at 2 mg/kg (Weeks 0, 4, then q8w) for active PsA to achieve standard clinical responses (ACR20, ACR50, etc.) would have been obvious to a POSA as of the priority date. The specific percentages of patients achieving these responses and the "treatment difference" compared to placebo (as recited in claims 2, 4, 5, and 6) represent the results of an obvious clinical study, rather than an inventive concept itself. These results would have been considered predictable variations of expected efficacy for an already-approved drug in a related indication, especially given that the clinical trial to generate these results was already in progress or its design was known in the art.

Conclusion

Based on the available prior art, the methods and compositions claimed in US patent 11041020, particularly the use of intravenous golimumab (Simponi Aria) at 2 mg/kg (Weeks 0, 4, then every 8 weeks) for the treatment of active Psoriatic Arthritis to achieve specific clinical endpoints, would have been obvious to a person having ordinary skill in the art by the priority date of January 30, 2017. The combination of established subcutaneous golimumab for PsA, established intravenous golimumab for RA (with the same dosage regimen), and the known pathophysiology of PsA would have provided a strong motivation for a POSA to apply IV golimumab to treat active PsA. The clinical outcomes described in the claims represent the expected efficacy of such a known drug in a closely related condition, especially when a Phase 3 clinical trial specifically investigating this use was already known in the art.